← FDA DRUG APPROVALS

FDA NDA · NDA006317

SULFONAMIDES DUPLEX

Sponsor: LILLY

APPLICATION
NDA006317
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
SUSPENSION, TABLET
MARKETING STATUS
Discontinued

Products

SULFONAMIDES DUPLEXDiscontinued
SULFADIAZINE 250MG/5ML, SULFAMERAZINE 250MG/5ML · SUSPENSION · ORAL
NEOTRIZINEDiscontinued
TRISULFAPYRIMIDINES (SULFADIAZINE 167MG, SULFAMERAZINE 167MG, SULFAMETHAZINE) 167MG · TABLET · ORAL
NEOTRIZINEDiscontinued
TRISULFAPYRIMIDINES (SULFADIAZINE 167MG/5ML, SULFAMERAZINE 167MG/5ML, SULFAMETHAZINE) 167MG/5ML · SUSPENSION · ORAL
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →